BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19826210)

  • 1. Hepatocellular carcinoma in Keio affiliated hospitals--diagnosis, treatment, and prognosis of this disease.
    Saito H; Masuda T; Tada S; Ebinuma H; Yamagishi Y; Ojiro K; Inoue M; Hibi T
    Keio J Med; 2009 Sep; 58(3):161-75. PubMed ID: 19826210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact.
    Utsunomiya T; Shimada M; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M;
    Ann Surg; 2014 Feb; 259(2):336-45. PubMed ID: 23673768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma.
    Chan AW; Chong CC; Mo FK; Wong J; Yeo W; Johnson PJ; Yu S; Lai PB; Chan AT; To KF; Chan SL
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1766-1772. PubMed ID: 26992142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
    J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma.
    Akahoshi H; Taura N; Ichikawa T; Miyaaki H; Akiyama M; Miuma S; Ozawa E; Takeshita S; Muraoka T; Matsuzaki T; Ohtani M; Isomoto H; Matsumoto T; Takeshima F; Nakao K
    Oncol Rep; 2010 May; 23(5):1317-23. PubMed ID: 20372846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases.
    Fenoglio L; Serraino C; Castagna E; Cardellicchio A; Pomero F; Grosso M; Senore C
    World J Gastroenterol; 2013 Jun; 19(21):3207-16. PubMed ID: 23745022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma.
    Wang CH; Wey KC; Mo LR; Chang KK; Lin RC; Kuo JJ
    Asian Pac J Cancer Prev; 2015; 16(9):3595-604. PubMed ID: 25987009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study.
    Mgaieth S; Kemp W; Gow P; Fink M; Lubel J; Nicoll A; Gazzola A; Hong T; Ryan M; Knight V; Dev AT; Sood S; Bell S; Paul E; Roberts SK
    J Viral Hepat; 2017 Nov; 24(11):982-989. PubMed ID: 28414893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients.
    Utsunomiya T; Shimada M; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Takayama T; Kokudo N;
    Ann Surg; 2015 Mar; 261(3):513-20. PubMed ID: 25072437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and prognosis of patients in Japan with viral marker-negative hepatocellular carcinoma.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Yamaguchi A; Isogai M; Kaneoka Y; Washizu J
    J Gastroenterol Hepatol; 2008 Mar; 23(3):459-66. PubMed ID: 17854425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
    Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
    J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population.
    Urakawa H; Kora SI; Mitsufuji T; Osame A; Higahsihara H; Yoshimitsu K
    Acta Radiol; 2016 Dec; 57(12):1445-1452. PubMed ID: 26861204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
    Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
    Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score.
    Kitai S; Kudo M; Minami Y; Ueshima K; Chung H; Hagiwara S; Inoue T; Ishikawa E; Takahashi S; Asakuma Y; Haji S; Osaki Y; Oka H; Seki T; Kasugai H; Sasaki Y; Matsunaga T
    Intervirology; 2008; 51 Suppl 1():86-94. PubMed ID: 18544953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study.
    Tateishi R; Okanoue T; Fujiwara N; Okita K; Kiyosawa K; Omata M; Kumada H; Hayashi N; Koike K
    J Gastroenterol; 2015 Mar; 50(3):350-60. PubMed ID: 24929638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area.
    Huang YH; Wu JC; Chen CH; Chang TT; Lee PC; Chau GY; Lui WY; Chang FY; Lee SD
    Liver Int; 2005 Apr; 25(2):236-41. PubMed ID: 15780044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic].
    Petry W; Heintges T; Hensel F; Erhardt A; Wenning M; Niederau C; Häussinger D
    Z Gastroenterol; 1997 Dec; 35(12):1059-67. PubMed ID: 9487638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
    Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
    J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.